Choose Your Country or Region

PLK

Choose Selective PLK Inhibitors

PLK Signaling Pathway Map

Isoform-selective Inhibitors

PLK Products

All (13)
PLK Inhibitors (13)
New PLK Products

Catalog No.	Product Name	Information	Product Use Citations
S1109	BI 2536	BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. BI-2536 inhibits Bromodomain 4 (BRD4) with Kd of 37 nM and potently suppresses c-Myc expression. BI-2536 induces apoptosis and attenuates autophagy. Phase 2.	Science, 2021, 371(6535)eabc5386 Nat Commun, 2021, 12(1):5356 Proc Natl Acad Sci U S A, 2021, 118(34)e2108145118
S1362	Rigosertib (ON-01910)	Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells. Phase 3.	Elife, 2021, 10e70715 Immun Inflamm Dis, 2021, 10.1002/iid3.458 Mol Cell, 2020, 79(1):191-198.e3
S1485	HMN-214	HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.	Exp Mol Med, 2020, 10.1038/s12276-020-00537-z Stem Cells Dev, 2019, 28(7):438-453 Oncotarget, 2017, 8(58):97928-97940
S2193	GSK461364	GSK461364 (GSK461364A) inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.	Cell Rep, 2021, 36(12):109740 Cancer Discov, 2021, candisc.1540.2020 Int J Radiat Oncol Biol Phys, 2021, S0360-3016(21)00203-0
S2235	Volasertib (BI 6727)	Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.	Science, 2021, 371(6535)eabc5386 Mol Cell, 2021, S1097-2765(20)30946-1 Nat Commun, 2021, 12(1):5356
S2758	Wortmannin (KY 12420)	Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.	Proc Natl Acad Sci U S A, 2022, 119(3)e2114134119 Adv Sci (Weinh), 2021, e2004303 J Extracell Vesicles, 2021, 10(8):e12091
S2898	MLN0905	MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.	Science Bulletin, 2018, 10.1016/j.scib.2018.09.024 Hepatology, 2017, 10.1002/hep.29236
S5807	HMN-176	HMN-176 is an active metabolite of HMN-214, which has a potent antitumor activity in mouse xenograft models. HMN-176 effectively inhibits PLK-1 by interference with its normal subcellular spatial distribution at centrosomes and along the cytoskeletal structure.
S7248	Ro3280	RO3280 (Ro5203280) is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.	J Med Chem, 2021, 10.1021/acs.jmedchem.1c01096 Oncotarget, 2018, 9(47):28731-28744 J Cell Mol Med, 2017, 21(4):758-767
S7255	Onvansertib (NMS-P937)	Onvansertib (NMS-P937, PCM-075, NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Onvansertib (NMS-P937) potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits tumor growth. Phase 1.	Theranostics, 2021, 11(19):9571-9586 Cell Res, 2019, 29(9):725-738 Sci Rep, 2018, 8(1):3521
S7552	CFI-400945	CFI-400945 is an orally active, potent and selective polo-like kinase 4(PLK4) inhibitor with Ki value of 0.26 nM.	Cell Death Dis, 2021, 12(7):640 J Cell Mol Med, 2020, 10.1111/jcmm.14996 Cancer Med, 2019, 8(14):6476-6484
S7720	SBE 13 HCl	SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.	PLoS Pathog, 2021, 17(7):e1009764 Reprod Biol Endocrinol, 2021, 19(1):162 Sci Adv, 2020, 6(29):eaba1941
S7837^New	Centrinone (LCR-263)	Centrinone (LCR-263) is a selective and reversible polo-like kinase 4 (PLK4) inhibitor with Ki of 0.16 nM.
S1109	BI 2536	BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. BI-2536 inhibits Bromodomain 4 (BRD4) with Kd of 37 nM and potently suppresses c-Myc expression. BI-2536 induces apoptosis and attenuates autophagy. Phase 2.	Science, 2021, 371(6535)eabc5386 Nat Commun, 2021, 12(1):5356 Proc Natl Acad Sci U S A, 2021, 118(34)e2108145118
S1362	Rigosertib (ON-01910)	Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells. Phase 3.	Elife, 2021, 10e70715 Immun Inflamm Dis, 2021, 10.1002/iid3.458 Mol Cell, 2020, 79(1):191-198.e3
S1485	HMN-214	HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.	Exp Mol Med, 2020, 10.1038/s12276-020-00537-z Stem Cells Dev, 2019, 28(7):438-453 Oncotarget, 2017, 8(58):97928-97940
S2193	GSK461364	GSK461364 (GSK461364A) inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.	Cell Rep, 2021, 36(12):109740 Cancer Discov, 2021, candisc.1540.2020 Int J Radiat Oncol Biol Phys, 2021, S0360-3016(21)00203-0
S2235	Volasertib (BI 6727)	Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.	Science, 2021, 371(6535)eabc5386 Mol Cell, 2021, S1097-2765(20)30946-1 Nat Commun, 2021, 12(1):5356
S2758	Wortmannin (KY 12420)	Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.	Proc Natl Acad Sci U S A, 2022, 119(3)e2114134119 Adv Sci (Weinh), 2021, e2004303 J Extracell Vesicles, 2021, 10(8):e12091
S2898	MLN0905	MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.	Science Bulletin, 2018, 10.1016/j.scib.2018.09.024 Hepatology, 2017, 10.1002/hep.29236
S5807	HMN-176	HMN-176 is an active metabolite of HMN-214, which has a potent antitumor activity in mouse xenograft models. HMN-176 effectively inhibits PLK-1 by interference with its normal subcellular spatial distribution at centrosomes and along the cytoskeletal structure.
S7248	Ro3280	RO3280 (Ro5203280) is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.	J Med Chem, 2021, 10.1021/acs.jmedchem.1c01096 Oncotarget, 2018, 9(47):28731-28744 J Cell Mol Med, 2017, 21(4):758-767
S7255	Onvansertib (NMS-P937)	Onvansertib (NMS-P937, PCM-075, NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Onvansertib (NMS-P937) potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits tumor growth. Phase 1.	Theranostics, 2021, 11(19):9571-9586 Cell Res, 2019, 29(9):725-738 Sci Rep, 2018, 8(1):3521
S7552	CFI-400945	CFI-400945 is an orally active, potent and selective polo-like kinase 4(PLK4) inhibitor with Ki value of 0.26 nM.	Cell Death Dis, 2021, 12(7):640 J Cell Mol Med, 2020, 10.1111/jcmm.14996 Cancer Med, 2019, 8(14):6476-6484
S7720	SBE 13 HCl	SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.	PLoS Pathog, 2021, 17(7):e1009764 Reprod Biol Endocrinol, 2021, 19(1):162 Sci Adv, 2020, 6(29):eaba1941
S7837^New	Centrinone (LCR-263)	Centrinone (LCR-263) is a selective and reversible polo-like kinase 4 (PLK4) inhibitor with Ki of 0.16 nM.
S7837^New	Centrinone (LCR-263)	Centrinone (LCR-263) is a selective and reversible polo-like kinase 4 (PLK4) inhibitor with Ki of 0.16 nM.